The American Journal of Managed Care

Angiogenesis Inhibitors Not Linked to Arterial Dissections, Aneurysms in Colorectal Cancer

Angiogenesis inhibitors showed no increased risk of arterial dissections or aneurysms in metastatic colorectal cancer patients. The study involved 34,733 patients, with 195 cases matched to 1950 ...
Univeristy of Iowa Daily Iowan

Starving Cancer: How Angiogenesis Inhibitors Cut Off the Tumor’s Blood Supply

Cancer remains one of the most strong challenges existing in modern medicine as of today, making it necessary to innovate strategies to combat its relentless progression. Out of the many strategies ...
ascopubs.org

Development and validation of a tumor tissue based multivariate biomarker for predicting angiogenesis inhibitor clinical benefit in renal cell carcinoma (RCC).

The immune characteristic analysis of BAP1 mutated clear cell renal cell carcinoma. This is an ASCO Meeting Abstract from the 2024 ASCO Genitourinary Cancers Symposium. This abstract does not include ...
ascopubs.org

The appropriate therapeutic sequence with angiogenesis inhibitor and chemotherapy in patients with advanced gastric or gastroesophageal junction adenocarcinoma: Exploratory ...

The number of lymph node dissections related to survival of patients with locally advanced esophageal squamous cell carcinoma after neoadjuvant therapy: A single-center study. This is an ASCO Meeting ...
The Scientist

Fighting Cancer with Angiogenesis Inhibitors

This past February, for example, Sugen, a division of Peapack, NJ-based Pharmacia, announced it was aborting its Phase III colorectal cancer clinical trial of SU5416, as no clinical benefit was found.